Drug Glucuronidation in Clinical Psychopharmacology

@article{Liston2001DrugGI,
  title={Drug Glucuronidation in Clinical Psychopharmacology},
  author={Heidi L. Liston and John Seth Markowitz and C. Lindsay DeVane},
  journal={Journal of Clinical Psychopharmacology},
  year={2001},
  volume={21},
  pages={500-515}
}
Glucuronidation is a phase II metabolic process and one of the most common pathways in the formation of hydrophilic drug metabolites. At least 33 families of uridine diphosphate-glucuronosyltransferases have been identified in vitro, and specific nomenclature similar to that used to classify the cytochrome (CYP) P450 system has been established. The UGT1 and UGT2 subfamilies represent the most important of these enzymes in human drug metabolism. Factors affecting glucuronidation include the… 

Glucuronidation enzymes, genes and psychiatry.

  • J. de Leon
  • Biology
    The international journal of neuropsychopharmacology
  • 2003
TLDR
The importance of glucuronidation and the implications for psychiatry is illustrated as UGTs appear to be in small concentrations in brain tissue (and higher concentrations at brain capillaries).

Glucuronidation enzymes, genes and psychiatry.

TLDR
The importance of glucuronidation and the implications for psychiatry is illustrated as UGTs appear to be in small concentrations in brain tissue (and higher concentrations at brain capillaries).

The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers

TLDR
The primary aim of this study was to evaluate the disposition of olanzapine or risperidone in healthy volunteers with and without coadministration of the uridine diphosphoglucuronate–glucuronosyltransferase inhibitor probenecid.

Psychotropic Drug Interactions With Valproate

TLDR
An overview of the noted pharmacokinetic psychotropic interactions with valproate is provided, with a particular focus on the mechanisms of these interactions and potential clinical consequences.

Metabolism and Disposition Kinetics of Nicotine

TLDR
Current knowledge about the metabolism and disposition kinetics of nicotine, some other naturally occurring tobacco alkaloids, and nicotine analogs that are under development as potential therapeutic agents are reviewed.

REGULATION OF GLUCURONIDATION (UGT1A9) PATHWAY DURING PREGNANCY

TLDR
The results showed a non-significant increase in the expression of UGT1A9 and in the formation of mycophenolic acid glucuronide from MPA in human hepatocytes treated with a combination of progesterone and estradiol.

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

TLDR
The objective of this article is to encourage those studying ligand interactions with UDP-glucuronosyltransferases (UGTs) to adequately consider the potential consequences of in vitro UGT inhibition in humans, taking the following into account: in vitro data on the enzymology of glucuronide formation from aglycone, pharmacokinetic principles based on empirical data for inhibition of metabolism, and clinical data for drug-drug interactions of drugs primarily cleared by glucuronidation.

Predicting reactivity to drug metabolism: beyond P450s—modelling FMOs and UGTs

TLDR
Results are validated by comparison with the experimentally observed reaction rates and sites of metabolism, indicating that the presented models are suitable to provide the basis of a reactivity component within generalizable models to predict either FMO or UGT metabolism.

Metabolic drug interactions with newer antipsychotics: a comparative review.

TLDR
Differences in the interaction potential among the novel antipsychotics currently available may be predicted based on their metabolic pathways, and the clinical relevance of these interactions should be interpreted in relation to the relative width of their therapeutic index.

CHARACTERIZATION OF AFLOQUALONE N-GLUCURONIDATION: SPECIES DIFFERENCES AND IDENTIFICATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE ISOFORM(S)

TLDR
It is demonstrated that AFQ N-glucuronidation in human is mainly catalyzed by UGT1A4 in the liver and by U GT1A3, as well as UGT2A3 in the intestine, as opposed to those in rat, dog, and monkey, respectively.
...

References

SHOWING 1-10 OF 138 REFERENCES

Drug glucuronidation in humans.

Glucuronidation of Drugs

TLDR
Examples of both direct and indirect contributions of glucuronides to net drug effects are described, indicating that morphine-6-glucuronide has analgesic activity and is a potent analgesic after administration to patients.

Glucuronidation: a dual control.

Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid

TLDR
In vitro studies support in vivo results and confirm that the inhibition takes place at the hepatic level when probenecid was added.

Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers.

TLDR
In vitro metabolic data, which support the in vivo results, are likely to contribute to reasonably predict the level of impairment of hepatic clearance in patients with liver cirrhosis.

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

TLDR
Findings indicate a genetic predisposition to the metabolism of irinotecan, suggesting that patients with low UGT1A1 activity, such as those with Gilbert's syndrome, may be at an increased risk for irinOTecan toxicity.

(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7.

TLDR
Inhibition studies suggest that the two diastereomeric glucuronidations are catalysed by different UGT isozymes, and there was competitive inhibition of (S)oxazepam glucuronidation by non-steroidal anti-inflammatory drugs (NSAIDs), including ketoprofen while (R)oxzepam glucoseuronidation was not equally inhibited by these compounds.

Human UGT2B7 catalyzes morphine glucuronidation.

TLDR
Cell homogenates and membrane preparations from HK 293 cells expressing UGT2B7 catalyzed the glucuronidation of morphine and other clinically significant opioid agonists, antagonists, and partial agonists.
...